¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : Ä¡·áº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
Estrogen Receptor Positive Breast Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå
:
1553538
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 08¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 110 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå ¼ºÀå ¹× µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀåÀº 2030³â±îÁö 337¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 7.89% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ ½ÃÀå¿¡´Â ÀÌ ¾ÆÇü À¯¹æ¾ÏÀ» Ç¥ÀûÈÇÏ°í °ü¸®Çϱâ À§ÇØ Æ¯º°È÷ °í¾ÈµÈ ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀÌ Æ÷ÇԵ˴ϴÙ.
¾à¹° °³¹ßÀÇ Çõ½ÅÀº ER À¯¹æ¾Ï Ä¡·á ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ý¿¡´Â »õ·Î¿î ¾Æ·Î¸¶Å¸Á¦ ¾ïÁ¦Á¦, ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ºÐÇØÁ¦(SERD), Ç¥ÀûÄ¡·áÁ¦ µîÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 1¿ù FDA´Â ESR1 º¯À̰¡ ÀÖ´Â ÀüÀ̼º ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º, HER2 À½¼º À¯¹æ¾Ï¿¡ ´ëÇÑ °æ±¸¿ë 󹿾àÀÎ ¿À¼¿µà¸¦ ½ÂÀÎÇÏ¿© °³ÀÎ ¸ÂÃãÇü Ä¡·á Àü·«À¸·ÎÀÇ ÀüȯÀ» °Á¶Çϰí ÀÖ½À´Ï´Ù.
Á¦¾à»ç, »ý¸í°øÇÐ ±â¾÷, ¿¬±¸±â°üÀÇ Àü·«Àû Á¦ÈÞ ¹× Çù·Â °ü°è´Â ER À¯¹æ¾Ï Ä¡·á ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 6¿ù ¸Þ³ª¸®´Ï ±×·ìÀÌ ÀνǸ®ÄÚ ¸Þµð½Å°ú ½Å±Ô KAT6A ¾ïÁ¦Á¦ °³¹ß¿¡ ´ëÇÑ ¶óÀ̼±½º °è¾àÀ» ü°áÇÑ °ÍÀº ¾Ï Ä¡·á Æ®·»µå¸¦ ¹ßÀü½Ã۱â À§ÇÑ °øµ¿ ³ë·ÂÀÇ Ãß¼¼¸¦ °Á¶ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÆÄÆ®³Ê½ÊÀº Á¾Á¾ ¾à¹° °³¹ßÀÇ °¡¼ÓÈ¿Í º¸´Ù Á¾ÇÕÀûÀÎ Ä¡·á ¿É¼ÇÀ¸·Î À̾îÁ® Àüü ER À¯¹æ¾Ï Ä¡·á ȯ°æÀ» °ÈÇÏ°í ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- Ä¡·á¹ýº°·Î´Â È£¸£¸ó ¿ä¹ýÀÌ 2023³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ±× ÀÌÀ¯´Â ȯÀÚ ¿¹ÈÄ °³¼± È¿°ú, ÈÇпä¹ý µî ´Ù¸¥ Ä¡·á¹ý¿¡ ºñÇØ ¿ì¼öÇÑ ºÎÀÛ¿ë ÇÁ·ÎÆÄÀÏ, À¯Áö¿ä¹ýÀ¸·Î¼ÀÇ Àå±âÀû Àû¿ë °¡´É¼º, °¡À̵å¶óÀÎÀÇ °·ÂÇÑ ÁöÁö, ÃÖ¼Òħ½ÀÀû Ä¡·á¹ý¿¡ ´ëÇÑ È¯ÀÚ ¼±È£µµ Áõ°¡, ºñ¿ë È¿À²ÀûÀÎ Ä¡·á¹ýÀ» µÞ¹ÞħÇÏ´Â °æÁ¦Àû °í·Á»çÇ×, °³ÀÎÈµÈ ÀÇ·á Á¢±Ù¹ýÀ» ÃËÁøÇÏ´Â ¹ÙÀÌ¿À¸¶Ä¿ Å×½ºÆ®ÀÇ ¹ßÀü ¸¦ ÃËÁøÇÏ´Â ¹ÙÀÌ¿À¸¶Ä¿ °Ë»çÀÇ ¹ßÀü, ÀÌ Ä«Å×°í¸®ÀÇ »õ·Î¿î Ä¡·á ¿É¼ÇÀ¸·Î À̾îÁö´Â Áö¼ÓÀûÀÎ ¿¬±¸ µîÀÌ ÀÖ½À´Ï´Ù.
- ÃÖÁ¾»ç¿ëÀÚº°·Î´Â º´¿øÀÌ 2023³â 62.48%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ±× ÀÌÀ¯´Â ´ÙÇÐÁ¦Àû ÆÀÀÇ Á¾ÇÕÀûÀÎ Ä¡·á Á¦°ø ´É·Â, ÀÓ»ó½ÃÇèÀ» Æ÷ÇÔÇÑ Ã·´Ü Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼º, º¹ÀâÇÑ ¿ä±¸¸¦ °¡Áø °í·É ȯÀÚ¸¦ ¼±È£ÇÏ´Â Àα¸Åë°èÇÐÀû ¿äÀÎ, º¸Çè Àû¿ë ¹× ºñ¿ë È¿À²¼º¿¡ ´ëÇÑ °æÁ¦Àû °í·Á, ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇÑ ¿¬±¸ °³¹ß ³ë·Â¿¡¼ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : Ä¡·áº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ¼¼°èÀÇ ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : Ä¡·á ´ë½Ãº¸µå
- ¼¼°èÀÇ ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : Ä¡·á º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : Ä¡·áº° ¸ÅÃâ
- ÈÇпä¹ý
- Ç¥Àû¿ä¹ý
- È£¸£¸ó¿ä¹ý
- ¹æ»ç¼± Ä¡·á
- ±âŸ
Á¦5Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ¼¼°èÀÇ ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : ÃÖÁ¾ ¿ëµµ ´ë½Ãº¸µå
- ¼¼°èÀÇ ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ¸ÅÃâ
- º´¿ø
- Àü¹® Ŭ¸®´Ð
- ±âŸ
Á¦6Àå ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï Ä¡·á ½ÃÀå : Ä¡·á ¹× ÃÖÁ¾ ¿ëµµº° Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ª ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018³â¿¡¼ 2030³â :
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦7Àå °æÀï »óȲ
- ±â¾÷/°æÀï ºÐ·ù
- º¥´õ »óȲ
- ÁÖ¿ä ÆÇ¸Å´ë¸®Á¡ ¹× ä³Î ÆÄÆ®³Ê ¸®½ºÆ®
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
- Radius Health, Inc.
- Sanofi
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Lilly
- EQRx, Inc.
- Gilead Sciences, Inc.
- Sermonix Pharmaceuticals
- Tyme Limited
- Genentech, Inc.
ksm
¿µ¹® ¸ñÂ÷
Estrogen Receptor Positive Breast Cancer Treatment Market Growth & Trends:
The global estrogen receptor positive breast cancer treatment market is anticipated to reach USD 33.7 billion by 2030 and is projected to grow at a CAGR of 7.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market includes a variety of therapeutic options specifically designed to target and manage this subtype of breast cancer.
Innovations in drug development are significantly impacting the ER+ breast cancer treatment market. New therapies include novel aromatase inhibitors, selective estrogen receptor degraders (SERDs), and targeted treatments. For instance, in January 2023, the FDA authorized Orserdu, an oral prescription for metastatic estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation, underscoring a shift towards personalized treatment strategies.
Strategic collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions significantly impact the market for ER+ breast cancer treatment. For instance, in June 2024, Menarini Group's licensing agreement with Insilico Medicine to develop a new KAT6A inhibitor underscores the trend toward collaborative efforts to advance oncology treatments. These partnerships often lead to accelerated drug development and more comprehensive treatment options, enhancing the overall treatment landscape for ER+ breast cancer and contributing to market expansion.
Estrogen Receptor Positive Breast Cancer Treatment Market Report Highlights:
- Based on treatment, hormonal therapy dominated the market in 2023 due to its efficacy in improving patient outcomes, favorable side effect profiles compared with other modalities such as chemotherapy, long-term applicability as maintenance therapy, strong guideline support, patient preference trends towards less invasive options, economic considerations favoring cost-effective treatments, advancements in biomarker testing facilitating personalized medicine approaches, and continuous research leading to new therapeutic options within this category.
- Based on end use, hospitals dominated the market with the largest revenue share of 62.48% in 2023 due to their ability to provide comprehensive care through multidisciplinary teams, access to advanced treatments including clinical trials, demographic factors favoring older patients with complex needs, economic considerations regarding insurance coverage and cost efficiency, and their pivotal role in R&D efforts to improve patient outcomes.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Treatment
- 1.2.2. End Use
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Treatment Outlook
- 2.2.2. End Use Outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Estrogen Receptor Positive Breast Cancer Treatment Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. High incidence and prevalence of ER+ breast cancer
- 3.2.1.2. Availability of endocrine therapies targeting ER
- 3.2.1.3. Increasing adoption of targeted therapies
- 3.2.2. Market restraint analysis
- 3.2.2.1. Limited treatment options for resistant cases
- 3.2.2.2. High costs associated with advanced therapies
- 3.3. Estrogen Receptor Positive Breast Cancer Treatment Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
Chapter 4. Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Estimates & Trend Analysis
- 4.1. Global Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Dashboard
- 4.2. Global Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Movement Analysis
- 4.3. Global Estrogen Receptor Positive Breast Cancer Treatment Market by Treatment, Revenue
- 4.4. Chemotherapy
- 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Targeted Therapy
- 4.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Hormonal Therapy
- 4.6.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Radiation Therapy
- 4.7.1. Radiation therapy market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Other
- 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Estimates & Trend Analysis
- 5.1. Global Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Dashboard
- 5.2. Global Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Movement Analysis
- 5.3. Global Estrogen Receptor Positive Breast Cancer Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
- 5.4. Hospitals
- 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Specialty Clinics
- 5.5.1. Specialty clinics market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Other
- 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Estrogen Receptor Positive Breast Cancer Treatment Market: Regional Estimates & Trend Analysis by Treatment, and End Use
- 6.1. Regional Dashboard
- 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 6.3. North America
- 6.3.1. U.S.
- 6.3.1.1. Key country dynamics
- 6.3.1.2. Regulatory framework/ reimbursement structure
- 6.3.1.3. Competitive scenario
- 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.2. Canada
- 6.3.2.1. Key country dynamics
- 6.3.2.2. Regulatory framework/ reimbursement structure
- 6.3.2.3. Competitive scenario
- 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.3. Mexico
- 6.3.3.1. Key country dynamics
- 6.3.3.2. Regulatory framework/ reimbursement structure
- 6.3.3.3. Competitive scenario
- 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4. Europe
- 6.4.1. UK
- 6.4.1.1. Key country dynamics
- 6.4.1.2. Regulatory framework/ reimbursement structure
- 6.4.1.3. Competitive scenario
- 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. Germany
- 6.4.2.1. Key country dynamics
- 6.4.2.2. Regulatory framework/ reimbursement structure
- 6.4.2.3. Competitive scenario
- 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.3. France
- 6.4.3.1. Key country dynamics
- 6.4.3.2. Regulatory framework/ reimbursement structure
- 6.4.3.3. Competitive scenario
- 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.4. Italy
- 6.4.4.1. Key country dynamics
- 6.4.4.2. Regulatory framework/ reimbursement structure
- 6.4.4.3. Competitive scenario
- 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.5. Spain
- 6.4.5.1. Key country dynamics
- 6.4.5.2. Regulatory framework/ reimbursement structure
- 6.4.5.3. Competitive scenario
- 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.6. Norway
- 6.4.6.1. Key country dynamics
- 6.4.6.2. Regulatory framework/ reimbursement structure
- 6.4.6.3. Competitive scenario
- 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.7. Sweden
- 6.4.7.1. Key country dynamics
- 6.4.7.2. Regulatory framework/ reimbursement structure
- 6.4.7.3. Competitive scenario
- 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.8. Denmark
- 6.4.8.1. Key country dynamics
- 6.4.8.2. Regulatory framework/ reimbursement structure
- 6.4.8.3. Competitive scenario
- 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Asia Pacific
- 6.5.1. Japan
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework/ reimbursement structure
- 6.5.1.3. Competitive scenario
- 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. China
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework/ reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. India
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework/ reimbursement structure
- 6.5.3.3. Competitive scenario
- 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.4. Australia
- 6.5.4.1. Key country dynamics
- 6.5.4.2. Regulatory framework/ reimbursement structure
- 6.5.4.3. Competitive scenario
- 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.5. South Korea
- 6.5.5.1. Key country dynamics
- 6.5.5.2. Regulatory framework/ reimbursement structure
- 6.5.5.3. Competitive scenario
- 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.6. Thailand
- 6.5.6.1. Key country dynamics
- 6.5.6.2. Regulatory framework/ reimbursement structure
- 6.5.6.3. Competitive scenario
- 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Latin America
- 6.6.1. Brazil
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework/ reimbursement structure
- 6.6.1.3. Competitive scenario
- 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.2. Argentina
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework/ reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. MEA
- 6.7.1. South Africa
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework/ reimbursement structure
- 6.7.1.3. Competitive scenario
- 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.2. Saudi Arabia
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework/ reimbursement structure
- 6.7.2.3. Competitive scenario
- 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.3. UAE
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework/ reimbursement structure
- 6.7.3.3. Competitive scenario
- 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.4. Kuwait
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework/ reimbursement structure
- 6.7.4.3. Competitive scenario
- 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Company/Competition Categorization
- 7.2. Vendor Landscape
- 7.2.1. List of key distributors and channel partners
- 7.2.2. Key company market share analysis, 2023
- 7.2.3. Radius Health, Inc.
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Sanofi
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. F. Hoffmann-La Roche Ltd
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. AstraZeneca
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. Lilly
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. EQRx, Inc.
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives
- 7.2.9. Gilead Sciences, Inc.
- 7.2.9.1. Company overview
- 7.2.9.2. Financial performance
- 7.2.9.3. Product benchmarking
- 7.2.9.4. Strategic initiatives
- 7.2.10. Sermonix Pharmaceuticals
- 7.2.10.1. Company overview
- 7.2.10.2. Financial performance
- 7.2.10.3. Product benchmarking
- 7.2.10.4. Strategic initiatives
- 7.2.11. Tyme Limited
- 7.2.11.1. Company overview
- 7.2.11.2. Financial performance
- 7.2.11.3. Product benchmarking
- 7.2.11.4. Strategic initiatives
- 7.2.12. Genentech, Inc.
- 7.2.12.1. Company overview
- 7.2.12.2. Financial performance
- 7.2.12.3. Product benchmarking
- 7.2.12.4. Strategic initiatives
°ü·ÃÀÚ·á